semaglutide serious side effects GI Adverse of Glucagon-Like Peptide-1 Receptor Agonists Ozempic Side Effects: Risks of

doi: 10.1152/ajpregu.00809.2010 40 ChenJWangXHeQBulusNFogoABZhangMZet al

Medical and regulatory references: FDA announcement on Foundayo/orforglipron approval JAMA report on FDA approval of oral orforglipron Novo Nordisk announcement on Wegovy pill approval and OASIS 4 results New England Journal of Medicine: Oral semaglutide 25 mg in adults with overweight or obesity JAMA Surgery: Obesity treatment with bariatric surgery vs GLP-1 receptor agonists NIDDK: Prescription medications to treat overweight and obesity ASMBS patient resources on metabolic and bariatric surgery

An update on the effect of incretin-based therapies on -cell function and mass

M.DavisS